Mar 13, 2019 / 09:30AM GMT
Sigurdur Oli Olafsson - Hikma Pharmaceuticals PLC - CEO & Executive Director
So good morning, everyone. Welcome. Thanks for joining us this morning. I know a few more faces than a year ago when I first joined the company, so to introduce myself, I'm Siggi Olafsson, the CEO of Hikma. With me today is Khalid Nabilsi, the CFO; part of the executive group of Hikma; and of course, the Investor Relation. Joining us for Q&A will be Said Darwazah, the Executive Chairman, so he will join us for the Q&A after the presentation.
So at the Capital Market Day, we presented the strategy for the group, and what I'm going to do is to give you an update to that strategy where we are, how we are progressing, then I will hand it over to Khalid to provide an overview of the financial performance of the group. And then, of course, we will open it up for questions.
So turning to Slide 3, this is our group highlights. The group has delivered a strong performance in 2018, with the revenue and profitability significant above the guidance that we set at this time last year. Across the group, we have
Full Year 2018 Hikma Pharmaceuticals PLC Earnings Call Transcript
Feb 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers